GlassScriptPhysician profile
Himanshi Chopra
NPI 1487158275
$3,193.11
in general payments reported to CMS, 2019-2025
23 companies · $424 in 2025
The $424 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $151 · 2020: $278 · 2021: $1,231 · 2022: $588 · 2023: $370 · 2024: $152 · 2025: $424.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $856 · Education: $89.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $856.41 |
| Education | $89.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $488.07 | 2021-2024 | Airsupra |
| Regeneron Healthcare Solutions, INC. | $464.02 | 2020-2022 | |
| Abbvie INC. | $287.92 | 2021-2024 | |
| Shield Therapeutics INC | $274.27 | 2022-2025 | Accrufer |
| Genzyme Corporation | $251.74 | 2020-2021 | |
| Novo Nordisk INC | $242.99 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Allergan, INC. | $222.00 | 2019-2021 | |
| Astellas Pharma US INC | $172.93 | 2024-2025 | Veozah |
| Alexion Pharmaceuticals, INC. | $138.73 | 2021 | |
| Glaxosmithkline, LLC. | $114.83 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $97.47 | 2021 | |
| Merck Sharp & Dohme LLC | $97.00 | 2019-2022 | |
| Boston Scientific Corporation | $51.27 | 2024-2025 | Wavewriter Alpha Prime 16 |
| Lilly USA, LLC | $50.59 | 2023-2025 | Mounjaro, Zepbound |
| Currax Pharmaceuticals LLC | $47.04 | 2023-2024 | Contrave, Onzetra Xsail |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $34.02 | 2025 | Xifaxan |
| Dexcom, INC. | $32.55 | 2022-2023 | Dexcom G6 Transmitter |
| Amgen INC. | $30.02 | 2025 | Repatha, Otezla |
| Silk Road Medical, INC. | $28.18 | 2023 | Enroute Transcarotid Stent, Enroute Transcarotid Neuroprotection System |
| Novartis Pharmaceuticals Corporation | $19.62 | 2021 | |
| Philips North America LLC | $18.34 | 2024 | (Ck7) Extended Holter |
| Linus Health, INC. | $17.18 | 2022 | |
| Bardy Diagnostics, INC. | $12.33 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Himanshi Chopra listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.